| Delivery of RNAs to specific organs by lipid nanoparticles for gene therapy K Godbout, JP Tremblay Pharmaceutics 14 (10), 2129, 2022 | 29 | 2022 |
| Prime editing for human gene therapy: where are we now? K Godbout, JP Tremblay Cells 12 (4), 536, 2023 | 26 | 2023 |
| CRISPR/Cas9 delivery strategies with engineered extracellular vesicles Y Lu, K Godbout, G Lamothe, JP Tremblay Molecular Therapy-Nucleic Acids, 2023 | 16 | 2023 |
| Successful Correction by Prime Editing of a Mutation in the RYR1 Gene Responsible for a Myopathy K Godbout, J Rousseau, JP Tremblay Cells 13 (1), 31, 2023 | 10 | 2023 |
| La correction de mutations pathogènes par Prime editing C Bouchard, K Godbout, JP Tremblay médecine/sciences 40 (10), 748-756, 2024 | | 2024 |
| Correcting pathogenic mutations using prime editing: an overview C Bouchard, K Godbout, JP Tremblay Medecine sciences: M/S 40 (10), 748-756, 2024 | | 2024 |
| The Advancement and Applications of Prime Editing Y Lu, C Bouchard, N Soucy, A Siddika, G Lamothe, K Godbout, ... | | 2024 |
| Development of a gene therapy treatment for RYR1-related diseases using prime editing K Godbout, J Rousseau, J Tremblay Journal of the Neurological Sciences 455, 2023 | | 2023 |
| First Correction by Prime Editing of a Mutation in the RYR1 Gene Responsible for a Myopathy K Godbout, J Rousseau, JP Tremblay Preprints, 2023 | | 2023 |
